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To evaluate structural changes in the retina and their correlation with visual dysfunction in
patients with multiple sclerosis.
Methods
Patients with multiple sclerosis (n = 84) and healthy controls (n = 84) underwent structural eval-
uation of the retinal nerve fiber layer, andmacular and ganglion cell layer thicknesses using
Spectral domain optical coherence tomography (SD-OCT). All subjects underwent high and
low contrast visual acuity, color vision (using the Farnsworth and L´Anthony desaturated D15
color tests), and contrast sensitivity vision using the Pelli Robson chart and CSV 1000E test.
Results
Macular, retinal nerve fiber layer, and ganglion cell layer thinning was observed in multiple
sclerosis patients compared to healthy controls (p<0.05). High- and low-contrast visual acu-
ity and contrast sensitivity vision at four different spatial frequencies were significantly
reduced in comparison with healthy subjects (p<0.05). Macular, retinal nerve fiber layer and
ganglion cell layer measurements correlated with high and low contrast visual acuity, and
contrast sensitivity vision. Contrast sensitivity vision was the functional parameter that most
strongly correlated with the structural measurements in multiple sclerosis and was associ-
ated with ganglion cell layer measurements. The L´Anthony color vision score (age-cor-
rected color confusion index) was associated with macular measurements.
Conclusions
Patients with multiple sclerosis had visual dysfunction that correlated with structural
changes evaluated by SD-OCT. Macular and ganglion cell layer measurements may be
good indicators of visual impairment in multiple sclerosis patients.
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Introduction
Optic nerve atrophy and thinning of the peripapillary retinal nerve fiber layer (RNFL) are two
typical findings of patients with multiple sclerosis (MS), with or without a history of optic neu-
ritis (ON). Axonal loss is considered to be the main cause of disability in MS.[1–3] Neuronal
loss is, however, increasingly recognized as a biomarker that correlates with disability in MS
patients.[4–7]
MS is often associated with involvement of the visual pathway that can lead to clinically evi-
dent manifestations (such as ON and diplopia) and, more frequently, to subclinical alterations.
Several studies have reported a correlation between axonal loss observed in the optic nerve and
visual dysfunction in MS.[1,8]. More recently, segmentation analysis of the various retinal lay-
ers made possible by new software for digital imaging techniques in ophthalmology have pro-
vided a more specific measurement of the retinal ganglion cell layer and the inner plexiform
layer complex (GCIPL) and suggest a correlation not only between axonal but also neuronal
loss and visual dysfunction in MS patients.[9,10]
In the present study, we assessed macular, RNFL, and GCIPL thicknesses measured by Spec-
tral domain-optical coherence tomography (SD-OCT) using segmentation analysis and evalu-
ated the correlation between structural measurements and visual dysfunction in MS patients.
Material and Methods
Patients with definite MS and age and sex matched healthy individuals were included in the
study. All procedures adhered to the tenets of the Declaration of Helsinki, and the experimental
protocol was approved by the Ethics Committee of the Miguel Servet Hospital. All participants
provided written informed consent to participate in the study. One eye per subject was ran-
domly selected and included in the study.
The diagnosis of MS was based on standard clinical and neuroimaging criteria and related
medical records were carefully evaluated. Information about Expanded Disability Status Scale
(EDSS) scores, disease duration, treatments, acute MS attacks, and prior episodes of ON were
recorded. The diagnosis of ON was based on clinical findings, which included the presence of
decreased visual acuity, relative afferent pupil defect, color vision loss, visual field defect, and a
compatible fundus examination. Patients with active ON in the 6 months preceding enrollment
in the study or during follow-up were excluded from the study. Participants had no concomi-
tant ocular diseases and no history of glaucoma, retinal pathology, or systemic conditions that
could affect the visual system. Eyes with significant refractive errors (>5 D of spherical equiva-
lent refraction or>3 D of astigmatism) were not included in the study.
All subjects underwent a complete neuro-ophthalmic evaluation that included pupillary,
anterior segment, and funduscopic examination. We assessed high contrast (HCVA) and low
contrast visual acuity (LCVA) using ETDRS and Low-Contrast Sloan Letter Charts, contrast
sensitivity vision (CSV) using CVS 1000E and Pelli Robson charts, and color vision (CV) using
Farnsworth-Munsell D15 and Lanthony D15 tests. Structural analysis of the retina was per-
formed with SD-OCT using the Cirrus High Definition (HD) OCT (Carl Zeiss Meditec Inc,
Dublin, CA), which included 3 applications: macular application (for macular thickness analy-
sis), and RNFL and ganglion cell applications (for individual analysis of these layers). All func-
tional and structural tests were performed during a single visit per patient and measurements
were obtained under monocular vision using best correction.
LogMAR visual acuity (VA) was evaluated at three different contrast levels: 100% (HCVA,
using ETDRS chart), 2.50%, and 1.25% (LCVA, using Low-Contrast Sloan Letter Charts -Preci-
sion Vision, LaSalle, IL-), The percentage indicating the level of contrast, i.e., 100% represent-
ing black letters over white background and 1.25% light grey letters over white background. All
OCT and Visual Dysfunction in Multiple Sclerosis
PLOS ONE | DOI:10.1371/journal.pone.0157293 June 28, 2016 2 / 14
measurements were obtained under controlled lighting conditions (photopic: mean luminance
of 85 cd/m2, high mesopic: 5 cd/m2, and low mesopic: 3 cd/m2).
CSV was evaluated using the Pelli-Robson chart and the CVS 1000E test. The Pelli-Robson
chart comprises horizontal lines of capital letters organized into groups of three (triplets) with
two triplets per line. Within each triplet, all letters have the same contrast. The contrast
decreases from one triplet to the next, even within each line. All patients were evaluated at a
distance of 1 meter from the chart, under controlled photopic conditions (85 cd/m2). The score
corresponding to the last triplet of letters seen by the patient was recorded.
The CSV 1000E instrument is used worldwide for standardized CSV and glare testing. All
patients were evaluated at a distance of 2.5 meters from the chart, at four spatial frequencies (3,
6, 12, and 18 cycles per degree [cpd]). The chart comprises 4 rows with 17 circular patches
each. The patches present a grating that decreases in contrast moving from left to right across
the row. The patient indicates whether the grating appears in the top patch or the bottom
patch for each column. Each contrast value for each spatial frequency was transformed into a
logarithmic scale according to standardized values.
Color vision was assessed using the Color Vision Recorder program (CVR, Optical Diagnos-
tics, Beusichem, The Netherlands). CVR software is designed for theWindows operating system
and analyzes chromatic discrimination by classification of colors. CVR includes several classic
color tests. All patients in the study were evaluated using the Farnsworth D15 and L´Anthony
D15 protocols (often used to differentiate between subjects with severe loss of color vision and
those with milder color defects or normal color vision) and different output parameters, such as
the Age-Corrected Color Confusion index (AC CCI, which represents the ratio between the
patient’s major radius–largest difference between caps–and the major radius of a perfect arrange-
ment for the subject’s age group), the Confusion angle (Conf angle, which represents the axis of
color deficiency), and the Scatter index (S-index, which represents the parallelism of confusion
vectors to the personal confusion angle) were recorded.[11,12] All these parameters evaluate the
severity of dyschromatopsia. For example, an AC CCI score higher than 1, indicates altered color
vision perception; the higher the score in the AC CCI and the S-index, the worse the condition.
Structural measurements of the retina were obtained using the Cirrus OCT device. The
same experienced operator performed all scans and did not apply manual correction to the
OCT output. We used an internal fixation target because it provides the highest reproducibility
and rejected poor quality scans prior to data analysis.[13] We based image quality assessment
on the signal strength measurement that combines the signal-to-noise ratio with the uniformity
of the signal within a scan (scale 1–10, where 1 is categorized as poor image quality and 10 as
excellent). We included images with a score7 for evaluation. The Cirrus OCT macular cube
512 x 128 protocol provides a macular volume measure and retinal thickness values for 9 areas
that correspond to the ETDRS. These areas include a central 1 mm circle representing the
fovea, and inner and outer rings measuring 3 mm and 6 mm in diameter, respectively. The
inner and outer rings are divided into four quadrants each: superior, nasal, inferior, and tempo-
ral. The Cirrus OCT optic disc protocol generates 200 x 200 cube images with 200 linear scans
enabling analysis of the RNFL of a 6-mm3 area around the optic nerve. For each scan series of
RNFL measurements, we assessed the average, superior, inferior, temporal, and nasal thickness.
The Cirrus segmentation analysis for retinal layers also provides measurements of the GCIPL
thickness, evaluating six areas of the macular cube (superior, superonasal, inferonasal, inferior,
inferotemporal, and superotemporal sectors). The segmentation analysis also includes mea-
surements of the average and minimum GCIPL. These values are obtained from a set of 360
spokes, where each average represents the mean number of the pixels along that spoke that lies
within the measurement annulus. The average and minimum values were selected because they
are more sensitive than other retinal measurements for detecting retinal thickness changes.[14]
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All data analyses were performed using SPSS software version 20.0 (SPSS Inc., Chicago, IL).
The Kolmogorov-Smirnov test was used to assess sample distribution. Differences between
evaluations of MS patients and healthy subjects were compared using the Student´s t test.
Patients were divided in two groups (history of ON vs no history of ON) and a second analysis
to calculate the differences between these two groups was performed using the Student´s t test.
The linear correlation between structural and functional parameters was determined using the
Pearson correlation coefficient. P values less than 0.05 were considered to indicate statistical
significance. To avoid a high false positive rate, the Bonferroni correction for multiple compari-
sons was calculated and the corrected p values were added to the previously calculated data.
Each eye was considered separately, and one eye from each patient was randomly selected
for analysis.
Results
Eighty-four patients with MS and 84 healthy controls were included in the study. The mean
age of the patients with MS was 45.69 (SD = 9.60) and the mean age of the healthy controls was
47.86 (SD = 9.62). Age, sex, and intraocular pressure did not differ significantly between
healthy controls and patients with MS (p = 0.140; 0.090 and 0.770 respectively).
All patients had been diagnosed with MS relapse-remitting subtype and were under treat-
ment with interferon 1b (14.3%), glatiramer acetate (4.7%), fingolimod (39.3%), or interferon
1a (10.7%). Only 28.6% of the patients were not under any current treatment. Mean EDSS
score was 1.64 (SD: 2.07) and 58% of the patients (n = 49) had a previous ON episode.
Functional parameters
MS patients showed significant reduction in best-corrected visual acuity at the three contrast
levels compared to the controls (0.14±0.67 in patients vs -0.09 ± 0.09 in controls at 100%,
p = 0.010; 0.55±0.17 vs 0.42±0.12 at 2.5%, p<0.001; 0.71±0.16 vs 0.55±0.14 at 1.25%,
p<0.001). CSV was affected in patients in all four spatial frequencies of the CSV 1000E chart
(3, 6, 12, and 18 cpd) when analyzed based on the number of correct localized gratings
(p<0.001). The Pelli Robson results revealed a significant reduction in CSV in MS patients
(p<0.001). L´Anthony AC-CCI and Conf angle results were also significantly worse in MS
patients. The results are shown in Table 1.
ANOVA was used to calculate differences between controls and patients with and without a
previous episode of ON (ON vs no-ON) (S1 Table). The EDSS score was significantly worse in
patients without a previous episode of ON (2.43±2.50 in patients without an ON episode vs
1.14 ±1.47 in patients with an ON episode, p<0.001). The post hoc analysis revealed that func-
tional parameters were only different between controls and patients (with and/or without a his-
tory of ON); no differences were observed between the two groups of patients (S1 Table).
Structural parameters
OCT measurements indicated significant differences in almost all macular sectors (except in
the central and outer temporal thickness; Table 1). The segmentation analysis revealed reduced
GCIPL thickness in MS patients in the inferotemporal (73.9±13.1 μm in patients vs 84.2
±6.7 μm in controls; p = 0.04) and superotemporal sectors (73.4±10.7 μm vs 83.9±6.2 μm;
p = 0.01). The minimum GCIPL value was significantly reduced (70.2±13.8 μm vs 82.4
±6.5 μm; p<0.001). The RNFL was significantly reduced in the average thickness and temporal
quadrant in MS patients (Table 1).
The ANOVA analysis revealed a significant difference in all GCIPL measurements (S2
Table). Post hoc analysis of macular measurements revealed significant differences between
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ETDRS 100 -0.09 (0.09) 0.14 (0.67) 0.010*
ETDRS 2.5 0.42 (0.12) 0.55 (0.17) <0.001*
ETDRS 1.25 0.55 (0.14) 0.71 (0.16) <0.001*
CONTRAST SENSITIVITY
Pelli Robson 1.89 (0.11) 1.74 (0.23) <0.001*
CSV 1000 3 cpd 1.73 (0.19) 1.44 (0.23) <0.001*
CSV 1000 6 cpd 1.98 (0.19) 1.50 (0.31) <0.001*
CSV 1000 12 cpd 1.62 (0.22) 1.00 (0.27) <0.001*
CSV 1000 18 cpd 1.16 (0.21) 0.56 (0.11) <0.001*
CHROMATIC VISION
CVR Farnsw AC CCI 1.11 (0.43) 1.13 (0.24) 0.660
CVR Farnsw ConfAngle 56.08 (7.93) 59.10 (8.63) 0.520
CVR Farnsw S- Index 1.66 (0.43) 1.74 (0.48) 0.310
CVR L’Anthony AC CCI 1.13 (0.36) 1.26 (0.30) 0.030
CVR L’Anthony ConfAngle 55.49 (4.02) 40.27 (6.49) 0.040
CVR L’Anthony S-Index 1.79 (0.50) 1.81 (0.41) 0.856
STRUCTURAL EXAMINATION
MACULAR THICKNESS
Fovea 257.07 (16.33) 249.01 (16.34) 0.012
Inner superior sector 325.99 (13.37) 309.86 (22.47) <0.001*
Inner nasal sector 326.35 (13.56) 309.61 (24.02) <0.001*
Inner inferior sector 321.96 (14.00) 304.44 (23.52) <0.001*
Inner temporal sector 311.14 (12.24) 297.67 (21.70) <0.001*
Outer superior sector 283.21 (11.66) 273.44 (19.06) <0.001*
Outer nasal sector 299.80 (14.97) 282.06 (23.60) <0.001*
Outer inferior sector 272.04 (13.02) 262.11 (27.91) 0.030
Outer temporal sector 264.79 (11.86) 254.67 (14.27) 0.540
Average 291.55 (15.70) 273.70 (18.47) <0.001*
Volume 10.12 (0.54) 9.88 (0.66) <0.001*
GCIPL THICKNESS
Superior sector 85.58 (6.67) 75.91 (8.46) 0.040
Superonasal sector 85.85 (7.46) 75.87 (9.25) 0.030
Inferonasal sector 84.61 (7.55) 75.26 (9.58) 0.140
Inferior sector 83.59 (7.70) 74.30 (9.56) 0.130
Inferotemporal sector 84.17 (6.73) 73.91 (13.11) 0.040
Superotemporal sector 83.87 (6.23) 73.35 (10.70) 0.010
Average GCIPL 84.68 (6.74) 74.87 (8.54) 0.080
Min GCIPL 82.42 (6.50) 70.17 (13.83) <0.001*
RNFL THICKNESS
Average 94.35 (9.62) 84.34 (13.14) 0.010*
Superior sector 117.10 (17.20) 107.08 (17.71) 0.550
Nasal sector 69.93 (11.79) 67.50 (14.07) 0.230
Inferior sector 124.1 (14.81) 107.63 (18.70) 0.010*
(Continued)
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healthy controls and patients (with and without a previous ON episode) in several sectors;
however, differences between the two subgroups of patients were only observed in the foveal
and average macular thickness, and macular volume.
Post hoc analysis of GCIPL thickness revealed statistical differences between controls and
patients (with and without a previous ON episode) in the superior and superonasal sectors,
and in the minimum GCIPL thickness.
Table 1. (Continued)
CONTROL MS P
Temporal sector 64.14 (8.94) 55.5 (18.52) <0.001*
Mean and standard deviation (SD) of visual function and structural parameters in healthy controls and subjects with multiple sclerosis. The Student T
test was performed to compare controls and patients with MS. Results in bold letters indicate statistical significance (p<0.050). Asterisk indicates a
significant difference by Student’s t test after Bonferroni correction for multiple tests (p0.017 for ETDRS; p0.010 for CSV 1000E measurements;
p0.0083 for Farnsworth and L´Anthony tests; p0.0056 for macular thickness values; p0.00625 for GCIPL thickness and p0.010 for RNFL
thickness). Abbreviations: ETDRS, Early Treatment Diabetic Retinopathy Study; cpd, cycles per degree; AC CCI, age-corrected color confusion index;
Conf Angle, confusion angle; S-index, scatter index; GCIPL, ganglion cell +inner plexiform layer; RNFL, retinal nerve fiber layer; HD, high definition;
MS, multiple sclerosis.
doi:10.1371/journal.pone.0157293.t001
Fig 1. Correlation between the average macular thickness and contrast sensitivity vision measured
with the Pelli Robson test in patients with multiple clerosis.Dark symbols represent data from patients
with a previous episode of optic neuritis, whereas light symbols represent patients without a previous episode
of optic neuritis.
doi:10.1371/journal.pone.0157293.g001
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Correlation between functional and structural parameters
CSV was the functional parameter most frequently associated with structural measurements in
MS. The Pelli Robson CSV results correlated with GCIPL thickness in all sectors and macular
thickness in 8 of 9 sectors, although the association was not strong (r< 0.5) (Figs 1 and 2). The
outer temporal (r = 0.41, p<0.001) and average macular thickness (r = 0.47, p<0.001) values
had the highest correlations. The Pelli Robson results also correlated with the thickness in dif-
ferent sectors of the RNFL (average, superior, inferior, and temporal sectors, r<0.50, p<0.05).
Measurements with the CSV 1000E at different spatial frequencies correlated significantly with
most GCIPL measurements (r<0.50). The superotemporal (r = 0.50, p< 0.001) thickness, aver-
age GCIPL thickness (r = 0.48, p< 0.001), and minimum GCIPL (r = 0.50, p< 0.001) thickness
had the strongest correlations at a spatial frequency of 18 cpd (Table 2).
Color vision was also associated with structural parameters: Farnsworth´s AC-CCI was
significantly associated with the GCIPL thickness (superior, superonasal, inferonasal, and
the average GCIPL thickness), although the association was not strong (r<0.30; Table 3).
L´Anthony´s AC-CCI was statistically correlated with different macular sectors (Table 3).
Macular average thickness showed the highest correlations with the color vision indexes
(Farnsworth´s AC-CCI r = -0.53, p<0.001 [data not shown in tables]; L´Anthony´s AC-CCI
r = -0.47, p<0.001). The color vision parameters were not significantly correlated with the
RNFL thickness.
Fig 2. Correlation between the average ganglion cell + inner plexiform layer thickness and contrast
sensitivity visionmeasured with the Pelli Robson test in patients with multiple sclerosis. Dark symbols
represent data from patients with a previous episode of optic neuritis, whereas light symbols represent
patients without a previous episode of optic neuritis.
doi:10.1371/journal.pone.0157293.g002
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VA using the ETDRS chart correlated with macular, GCIPL, and RNFL thickness (Table 4,
Fig 3). There were significant but mild associations between 8 of the 9 macular parameters and
LCVA at 2.50% and 1.25%, where the macular average thickness had the highest correlations
(r = -0.41, p = 0.01 and r = -0.36, p = 0.04, respectively).
Discussion
In the present study, we evaluated different structural and functional parameters and assessed
the association between visual dysfunction and morphologic changes in the retina of 84
patients with MS and 84 healthy controls. We demonstrated that structural parameters, such
as macular, RNFL, and GCIPL thicknesses, are reduced in MS patients, but they also exhibited
visual impairment (VA and CSV reduction). Moreover, contrast sensitivity was the most
affected parameter in our study and correlated with most of the structural data. We have used
color vision tests that provide information for differentiating subjects with severe loss of color
vision from those with milder color defects or normal color vision, and also can be used to
Table 2. Correlation between structural parameters and contrast sensitivity vision in patients with multiple sclerosis.
CSV 1000E test Pelli Robson
STRUCTURAL MEASUREMENTS 3 cpd P 6 cpd p 12 cpd p 18 cpd p r P
MACULAR THICKNESS
Fovea 0.15 0.080 0.15 0.080 0.12 0.180 0.18 0.040 0.12 0.150
Inner superior sector 0.32 <0.001* 0.41 <0.001* 0.41 <0.001* 0.42 <0.001* 0.36 <0.001*
Inner nasal sector 0.34 <0.001* 0.45 <0.001* 0.41 <0.001* 0.44 <0.001* 0.35 <0.001*
Inner inferior sector 0.32 <0.001* 0.42 <0.001* 0.42 <0.001* 0.41 <0.001* 0.35 <0.001*
Inner temporal sector 0.30 <0.001* 0.37 <0.001* 0.38 <0.001* 0.41 <0.001* 0.31 <0.001*
Outer superior sector 0.30 <0.001* 0.33 <0.001* 0.36 <0.001* 0.37 <0.001* 0.39 <0.001*
Outer nasal sector 0.35 <0.001* 0.43 <0.001* 0.38 <0.001* 0.44 <0.001* 0.34 <0.001*
Outer inferior sector 0.17 0.050 0.28 0.001* 0.27 0.002* 0.31 <0.001* 0.27 <0.001*
Outer temporal sector 0.33 <0.001* 0.30 <0.001* 0.40 <0.001* 0.41 <0.001* 0.41 <0.001*
Average 0.29 0.020 0.38 0.003* 0.39 0.002* 0.44 0.001* 0.47 <0.001*
Volume 0.17 0.180 0.34 0.006 0.27 0.030 0.30 0.018 0.15 0.230
GCIPL THICKNESS
Superior sector 0.22 0.020 0.37 <0.001* 0.37 <0.001* 0.44 <0.001* 0.40 <0.001*
Superonasal sector 0.21 0.030 0.38 <0.001* 0.36 <0.001* 0.41 <0.001* 0.38 <0.001*
Inferonasal sector 0.18 0.060 0.37 <0.001* 0.36 <0.001* 0.41 <0.001* 0.37 <0.001*
Inferior sector 0.19 0.050 0.41 <0.001* 0.35 <0.001* 0.45 <0.001* 0.38 <0.001*
Inferotemporal sector 0.23 0.020 0.36 <0.001* 0.34 0.001* 0.42 <0.001* 0.25 <0.001*
Superotemporal sector 0.31 0.002* 0.45 <0.001* 0.44 <0.001* 0.50 <0.001* 0.36 <0.001*
Average GCIPL 0.25 0.010 0.43 <0.001* 0.40 <0.001* 0.48 <0.001* 0.38 <0.001*
Min GCIPL 0.27 0.007 0.43 <0.001* 0.42 <0.001* 0.50 <0.001* 0.36 <0.001*
RNFL THICKNESS
Average 0.18 0.030 0.19 0.020 0.14 0.090 0.15 0.070 0.33 <0.001*
Superior sector 0.15 0.070 0.13 0.110 0.13 0.120 0.16 0.060 0.30 <0.001*
Nasal sector 0.02 0.790 0.08 0.350 0.16 0.060 0.15 0.070 0.08 0.310
Inferior sector 0.15 0.060 0.16 0.040 0.11 0.200 0.09 0.260 0.32 <0.001*
Temporal sector 0.24 0.004* 0.34 <0.001* 0.34 <0.001* 0.35 <0.001* 0.24 <0.001*
Correlation between structural parameters (macular, ganglion cell layer and retinal nerve fiber layer thickness) and contrast sensitivity vision (CSV)
evaluated with the CSV 1000E and Pelli Robson tests in patients with multiple sclerosis. Data in bold type correspond to statistically significant
correlations (p-value <0.05). Asterisk indicates a significant difference after Bonferroni correction for multiple tests (p0.0056 for macular thickness
values; p0.00625 for GCIPL thickness and p0.010 for RNFL thickness). Abbreviations: GCIPL, ganglion cell+inner plexiform layer; RNFL, retinal nerve
fiber layer; cpd, cycles per degree.
doi:10.1371/journal.pone.0157293.t002
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evaluate acquired loss of color vision. Both the Farnsworth and L´Anthony tests are color
arrangement tests (based on the arrangement of different color caps); however, the L´Anthony
color test is less saturated, and is thus more suitable for detecting mild color anomalies that
may not be detected using the Farnsworth color test alone. In our study, only the L´Anthony
test results (AC CCI and Conf angle) were significantly worse in the MS group compared to
healthy controls, showing a mild tendency toward protanomaly.
Visual dysfunction may occur in up to 80% of MS patients during the course of the disease.
[15] Diminished contrast sensitivity and color vision deficiencies in MS have been widely
reported.[16,17] Measures of low-contrast vision as tested by line gratings, letter charts, and by
Pelli-Robson charts in MS patients were sensitive to visual impairment, even in patients with
VA of 20/20 or better as measured with a Snellen chart. This alteration in low-contrast vision is
also associated with visual impairment of everyday tasks, such as reading, driving, and facial
recognition.[18] The introduction in the last few decades of OCT in the study of optic nerve
neuropathies has provided new information on correlations between visual deficiencies and
retinal alterations. Recent studies using OCT showed that low contrast letter acuity scores
reflect the axonal and neuronal losses in the anterior visual pathways.[9,19,20] This axonal loss
is also associated with disease progression, worsening disability, and lower quality of life in MS
patients [21,22].
Table 3. Correlation between structural measurements and color vision in patients with multiple
sclerosis.
FARNSWORTH COLOR TEST
GCIPL THICKNESS AC-CCI p
Superior sector -0.21 0.030
Superonasal sector -0.23 0.020
Inferonasal sector -0.23 0.010
Inferior sector -0.16 0.100
Inferotemporal sector -0.16 0.100
Superotemporal sector -0.21 0.030
Average GCIPL -0.23 0.020
Min GCIPL -0.13 0.190
L´ANTHONY COLOR TEST
MACULAR THICKNESS AC-CCI p
Fovea -0.01 0.900
Inner superior sector -0.21 0.020
Inner nasal sector -0.25 <0.001*
Inner inferior sector -0.22 0.010
Inner temporal sector -0.17 0.060
Outer superior sector -0.18 0.050
Outer nasal sector -0.10 0.290
Outer inferior sector -0.05 0.580
Outer temporal sector -0.06 0.530
Average thickness -0.47 <0.001*
Correlation between structural measurements (ganglion cell layer and macular thickness) and color vision
evaluated with the Farnsworth and L´Anthony color tests in patients with multiple sclerosis. Correlation
data in bold type are statistically significant (p-value <0.05). Asterisk indicates a significant difference after
Bonferroni correction for multiple tests (p0.00625 for GCIPL thickness and p0.0056 for macular
thickness values). Abbreviations: GCIPL, ganglion cell+inner plexiform layer; AC-CCI: age-corrected color
confusion index.
doi:10.1371/journal.pone.0157293.t003
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New SD-OCT segmentation software allows for the measurement of the various retinal lay-
ers. Previous studies on MS found a reduction in RNFL not only in eyes with a previous episode
of ON, but also in patients who have never had an acute clinical episode of ON.[23,24] Current
studies using segmentation analysis of the retinal layers have demonstrated a thinning of the
GCIPL, suggesting ganglion cell loss.[9,25,26] This GCIPL thinning was significantly associ-
ated with reduced visual function and vision-specific quality of life in MS patients. Additionally
GCIPL thinning occurs 3 to 6 months following acute ON.[10]
Histopathologic evaluation of postmortem MS eyes revealed the loss of inner nuclear layer
neurons and significant GCIPL atrophy [27], even in cases where the number of axons
remained intact.[28] Thus, GCIPL thickness has rapidly emerged as a useful structural marker
Table 4. Correlation between structural parameters and visual acuity in patients with MS.
STRUCTURAL
PARAMETERS
Visual Acuity ETDRS LogMar
100% p 2.50% p 1.25% p
MACULAR
THICKNESS
Central -0.07 0.400 -0.07 0.430 -0.05 0.530
Inner superior -0.09 0.310 -0.30 <0.001* -0.30 0.001*
Inner nasal -0.08 0.360 -0.28 0.001* -0.26 0.002*
Inner inferior -0.09 0.270 -0.32 <0.001* -0.30 <0.001*
Inner temporal -0.11 0.220 -0.25 0.003* -0.26 0.002*
Outer superior -0.06 0.460 -0.31 <0.001* -0.32 <0.001*
Outer nasal -0.04 0.670 -0.32 <0.001* -0.29 0.001*
Outer inferior -0.07 0.420 -0.26 0.002* -0.25 0.003*
Outer temporal -0.08 0.370 -0.33 <0.001* -0.31 <0.001*
Average -0.01 0.960 -0.41 0.001* -0.36 0.004*
Volume -0.04 0.720 -0.15 0.230 -0.08 0.520
GCIPL
THICKNESS
Superior -0.42 <0.001* -0.27 0.005* -0.27 0.006*
Superonasal -0.39 <0.001* -0.29 0.003* -0.28 0.005*
Inferonasal -0.39 <0.001* -0.31 0.001* -0.28 0.004*
Inferior -0.36 <0.001* -0.26 0.008 -0.14 0.150
Inferotemporal -0.26 0.008 -0.14 0.140 -0.10 0.299
Superotemporal -0.32 0.001* -0.23 0.020 -0.12 0.040
Average GCIPL -0.38 <0.001* -0.27 0.005* -0.23 0.020
Minimum GCIPL -0.31 0.001* -0.21 0.030 -0.15 0.130
RNFL
THICKNESS
Average -0.21 0.008* -0.27 0.001* -0.35 <0.001*
Superior -0.21 0.010* -0.28 <0.001* -0.33 <0.001*
Nasal -0.05 0.490 -0.04 0.630 -0.07 0.400
Inferior -0.26 0.001* -0.24 0.004* -0.29 <0.001*
Temporal -0.16 0.040 -0.19 0.020 -0.29 <0.001*
Correlation between structural parameters (macular, ganglion cell layer and retinal nerve fiber layer thickness) and visual acuity in different contrast levels
in patients with multiple sclerosis. Data in bold type correspond to statistically significant correlations (p value <0.05). Asterisk indicates a significant
difference after Bonferroni correction for multiple tests (p0.0056 for macular thickness values; p0.00625 for GCIPL thickness and p0.010 for RNFL
thickness). Abbreviations: ETDRS, Early Treatment Diabetic Retinopathy Study; GCIPL, ganglion cell+inner plexiform layer; RNFL, retinal nerve fiber layer.
doi:10.1371/journal.pone.0157293.t004
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in MS, even better than RNFL thickness. A positive correlation between the average GCIPL
and the peripapillary RNFL thickness was recently demonstrated.[14]. Additionally, GCIPL
thickness is suggested to have better sensitivity than temporal peripapillary RNFL thickness for
detecting retinal thickness changes in patients with MS.[14,29]. In the present study, macular
thickness was reduced in most sectors, but the peripapillary RNFL thickness was only reduced
in the inferior and temporal quadrants. Segmentation analysis of the GCIPL thickness revealed
a clear tendency towards a reduction in the superior and temporal (superotemporal and infero-
temporal) sectors (p<0.05) although only the minimum GCIPL thickness was significantly
reduced (p<0.001). These findings suggest a topographic match between defects in the GCIPL
and decreased peripapillary RNFL thickness, supporting previous research, where superior
macular areas (including superotemporal and superonasal sectors) anatomically correspond
with the RNFL bundle to the temporal quadrant in the optic disc.[30] The thickness of these
layers (especially the GCIPL) was also significantly worse in patients with a previous history of
ON, corroborating previously reported results.[10, 31] Our results did not demonstrate a
higher sensitivity of the GCIPL thickness to detect axonal damage. A clear tendency toward
GCIPL loss in patients with MS, however, was observed (higher than in the RNFL), and com-
parison between groups revealed greater effects on GCIPL thickness in subjects with previous
ON. Thus, further studies with a larger sample size are needed to confirm that the GCIPL
reduction is a better marker of axonal damage in these patients.
Fig 3. Correlation between visual acuity as measured with ETDRS optotipe at a contrast level of 100%
and the average ganglion cell + inner plexiform layer thickness in patients with multiple sclerosis.
Dark symbols represent data from patients with a previous episode of optic neuritis, whereas light symbols
represent patients without a previous episode of optic neuritis.
doi:10.1371/journal.pone.0157293.g003
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Correlations between visual dysfunction and structural measurements in MS have been also
reported,[9, 25, 26, 32, 33] although few of these studies include CSV and color vision analysis.
A reduction in the RNFL is associated with lower LCVA, alterations in color vision, and lower
quality of life in MS patients.[33, 34] The reduction of the macular and GCIPL thickness are
significantly correlated with VA (high and low contrast).[9,25,26] In accordance with these
previous studies, our results showed an association between macular and GCIPL thinning and
worse LCVA and CSV (measured by the CSV 1000E and Pelli Robson tests), highlighting the
importance of CSV tests and analysis of the GCIPL and macular thickness in the clinical evalu-
ation of MS patients. Moreover, in our study, macular and GCIPL thicknesses were inversely
correlated with L´Anthony and Farnsworth´s color indexes, respectively. These color tests evalu-
ate the severity of dyschromatopsia and are not frequently included in studies assessing visual
dysfunction and MS. In a recent study, the Farnsworth D-100 color test (based on the same prin-
ciple as the Farnsworth and L´Anthony D15 color tests) was demonstrated to be more sensitive
than pattern visual evoked potentials in detecting subclinical visual pathway alterations in MS
patients making this color test a valuable tool for evaluating these patients.[35]
In conclusion, MS patients had reduced macular, RNFL, and GCIPL thicknesses, with the
changes in the GCIPL being most closely associated with visual dysfunction. These results
may be important for future investigations of neuronal and axonal loss in MS and other neuro-
degenerative diseases. Further studies are needed to evaluate the association between axonal
injury and ganglion cell loss and to investigate the role of the GCIPL as a possible biomarker of
the efficacy of neuroprotective agents.
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